

## Introduction

Periprosthetic joint infection (PJI) is a devastating complication of total joint arthroplasty (TJA) as it substantially affects morbidity, impairs quality of life, and is often associated with significantly high clinical cost. Although PJI occurs at a relatively low rate with <3% of total hip or knee arthroplasties affected, given a steadily increasing volume of TJAs over time with 4 million total joint replacements estimated by 2030 in the US alone, the number of PJIs and their impact are significant.

PJI is difficult and challenging to treat because it is often associated with bacterial biofilms that provide a protective layer from host defense system or antimicrobial drugs. PJI can be caused by a variety of microorganisms, with *Staphylococcus epidermidis* and *Staphylococcus aureus* being the most common agents, accounting for 35 and 21% of monomicrobial PJI cases, respectively.

PJI diagnosis can be challenging and relies on a large combination of clinical findings. No single universal diagnostic test exists to provide accurate and timely diagnosis. Here we applied transcriptomic sequencing to investigate host response with aim of identifying unique molecular signatures for PJI.

## Specific Aims

Multimic analysis of biomaterials dislodged from surfaces of resected prosthetic hip or knee hardware (known as sonicate fluid):

1. Identify host genes exhibiting highly differential expression in PJI compared to aseptic cohort
2. Identify molecular signatures of staphylococcal compared to non-staphylococcal PJIs
3. Identify molecular signatures of *Staphylococcus aureus* compared to *Staphylococcus epidermidis* PJI

## Methods




Figure 1: Study design




Figure 2: Sample processing and analysis workflows

## Results

### Transcriptomic profiles of PJI versus aseptic failure




Figure 3: Principle component analysis of all PJI group (A), staphylococcal PJI (B), and non-staphylococcal PJI (C) versus aseptic failure. Green circles, PJI cases; yellow circles, aseptic failure cases.

### Expression of proposed PJI-related genes

57 PJI-associated genes defined in prior studies were assessed for expression in PJI versus aseptic cohort:

- 28 genes increased expression in PJI groups
  - PI3: most expressed gene across all PJI groups
  - MMP3 and IL17D: 2-3 fold higher expression in staphylococcal versus non-staphylococcal PJI
  - IL8 and IL1B: 3-4 fold higher expression in *S. aureus* PJI versus *S. epidermidis* and non-staphylococcal PJI subgroups
- 2 genes paradoxically downregulated (A2M and LDHD)
- 27 no significant change in expression

Table 1: Twenty-eight proposed PJI related genes with increased expression

Gene	All PJI	Staphylococcal PJI	Non-staphylococcal PJI	<i>S. aureus</i> PJI	<i>S. epidermidis</i> PJI	Gene	All PJI	Staphylococcal PJI	Non-staphylococcal PJI	<i>S. aureus</i> PJI	<i>S. epidermidis</i> PJI
PI3	910.3*	918.8*	1179*	2603*	799.6*	CSF2RB	3.5*	3.5*	3.8*	5.0*	2.8*
IL8	30.9*	30.3*	32.6*	86.8*	26.0*	LDHC	3.4*	4.4*	2.5*	n/r	n/r
IL5RA	29.8*	27.0*	33.6*	26.9*	27.6*	DEFA4	3.3*	2.7*	3.2*	4.3	1.6
IL1B	22.7*	20.7*	26.2*	67.5*	15.2*	LCN2	3.0*	2.4	3.3*	5.2*	1.5
IL1A	19.8*	17.2*	27.2*	35.6*	14.5*	CAMP	2.9*	2.3*	3.2*	3.9*	1.6
CSF3	10.7*	10.3*	13.4*	7.4*	4.9*	LTF	2.6*	2.1	3.0*	3.4	1.3
IL6	7.5*	8.3*	7.1*	13.0*	8.6*	VEGFA	2.6*	2.5*	2.8*	3.4*	2.2*
FCGR1B	5.6*	5.7*	5.9*	8.1*	6.1*	CXCL2	2.5*	2.4*	2.8*	3.2*	2.1*
BPI	5.3*	4.1*	6.3*	8.6*	2.6	CCL3	2.4*	2.1*	3.1*	3.7*	2
MMP3	4.8*	6.9*	2.7*	15.4*	4.9*	IL1RN	2.4*	2.5*	2.6*	5.1*	1.9
IL17D	4.7*	6.7*	3.5*	7.1*	8.6*	IFNG	2.2*	1.6	3.3*	n/r	n/r
CCL4	4.5*	4.1*	5.8*	8.1*	3.3*	IL2RA	2.2*	2.3*	2.3*	3.2*	2.3*
LBP	4.2*	5.4*	3.4*	9.1*	4.8*	ICAM1	2.1*	2.2*	2.0*	3.1*	2.1*
IL13RA2	3.9*	4.7*	3.3*	7.2*	n/r	IL2RG	2.0*	2.0*	2.3*	2.8*	1.7

### Expression analysis revealed novel markers for PJI

Table 2: Top 50 genes with highest expression in PJI cohorts

Staphylococcus/Non-Staphylococcus PJI			<i>S. aureus/S. epidermidis</i> PJI				
Both PJI groups	Staphylococcal PJI	Non-staphylococcal PJI	Both PJI groups	<i>S. aureus</i> PJI	<i>S. epidermidis</i> PJI		
<b>Immune function</b>							
F7, FCRL4	PI3, UMOD	CCL20	F7, FCRL4	PI3, UMOD, IL8, PF4V1, IL1B			
<b>Cell metabolism /proliferation/ regulation function</b>							
ARSI, ATOH7, CCN2, CELA1, DLX2, DMRTA2, EFNA2, EN1, GABRG3, GDF2, GPM6A, HDGFL1, HOXC13, LYPD4, NDST4	NEUROD1, NEUROD2, NKX2-5, NKX3-1, OR52E8, PAN3, PRSS56, S1PR2, SALL3, SLITRK1, SLITRK2, SPATA22, USP26, VAX1, WT1	SEPTIN3, CAMK2N2, FOXE3, HMX3, NKX1-2, ONECUT1, ONECUT3, TAG, TGM3	CDH10, CRNDE, FOXI3, GPR123, KRT20, MSI1, PHOX2B, SCN2A, SOX11	ARSI, ATOH7, CAMK2N2, CCN2, CELA1, DLX2, DMRTA2, EFNA2, EN1, FOXE3, GPM6A, HDGFL1, HOXC13, LYPD4	NEUROD1, NEUROD2, NKX2-5, NKX3-1, ONECUT3, OR52E8, PAN3, PRSS56, S1PR2, SALL3, SLITRK1, SLITRK2, SPATA22, TGM3, VAX1, WT1	CRNDE, CYP26C1, HOXC13, NKX1-2	SEPTIN3, C1QL1, ENPP7, HMX3, KCNG3, ONECUT1, PHOX2B, THEG
<b>Unknown function</b>							
BPESC1, DCAF4L2, LDLRAD1	MGC2889, NOL4, VSG10			BPESC1, DCAF4L2, LDLRAD1	MGC2889, PYP2, VSG10		

### Analysis of top expressed genes:

- F7, PI3, FCRL4, and UMOD: highly expressed in all PJI groups
- IL8, IL1B, and PF4V1: uniquely highly expressed in *S. aureus* PJI

### Pathway analysis




Figure 4: Top 10 enriched pathways in PJI cohort

Top enriched pathways involved:

- Host immune response (IL-17A pathway, granulocyte and agranulocyte adhesion)
- Cellular development and repair functions (osteoarthritis, cAMP, axonal guidance)

## Conclusions

1. PJI cohorts display uniquely distinct expression profiles from aseptic failure.
2. Multiomic analysis identified potential PJI molecular signatures:
  - ❑ Of previously-investigated PJI-related genes
    - ✓ PI3: most differentiating PJI from aseptic failure
    - ✓ MMP3 and IL17D: distinguish staphylococcal from non-staphylococcal PJI
    - ✓ IL8 and IL1B: potential signatures for *S. aureus* PJI
  - ❑ Top expressed genes,
    - ✓ F7, FCRL4 and UMOD: most expressed in PJI
    - ✓ IL8, IL1B and PF4V1: uniquely expressed in *S. aureus* PJI

## Funding

This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number R01 AR056647-06A1 and Musculoskeletal training grant T32 AR56950